Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study

Henri B. Wolff*, Leonie Alberts, Naomi van der Linden, Mathilda L. Bongers, Naomi E. Verstegen, Frank J. Lagerwaard, Frederik N. Hofman, Carin A. Uyl-de Groot, Suresh Senan, Sherif Y. El Sharouni, Elisabeth A. Kastelijn, Franz M.N.H. Schramel, Veerle M.H. Coupé

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)

Abstract

Objectives: Stage I non-small cell lung cancer (NSCLC) can be treated with either Stereotactic Body Radiotherapy (SBRT) or Video Assisted Thoracic Surgery (VATS) resection. To support decision making, not only the impact on survival needs to be taken into account, but also on quality of life, costs and cost-effectiveness. Therefore, we performed a cost-effectiveness analysis comparing SBRT to VATS resection with respect to quality adjusted life years (QALY) lived and costs in operable stage I NSCLC. Materials and methods: Patient level and aggregate data from eight Dutch databases were used to estimate costs, health utilities, recurrence free and overall survival. Propensity score matching was used to minimize selection bias in these studies. A microsimulation model predicting lifetime outcomes after treatment in stage I NSCLC patients was used for the cost-effectiveness analysis. Model outcomes for the two treatments were overall survival, QALYs, and total costs. We used a Dutch health care perspective with 1.5 % discounting for health effects, and 4 % discounting for costs, using 2018 cost data. The impact of model parameter uncertainty was assessed with deterministic and probabilistic sensitivity analyses. Results: Patients receiving either VATS resection or SBRT were estimated to live 5.81 and 5.86 discounted QALYs, respectively. Average discounted lifetime costs in the VATS group were €29,269 versus €21,175 for SBRT. Difference in 90-day excess mortality between SBRT and VATS resection was the main driver for the difference in QALYs. SBRT was dominant in at least 74 % of the probabilistic simulations. Conclusion: Using a microsimulation model to combine available evidence on survival, costs, and health utilities in a cost-effectiveness analysis for stage I NSCLC led to the conclusion that SBRT dominates VATS resection in the majority of simulations.

Original languageEnglish
Pages (from-to)89-96
Number of pages8
JournalLung Cancer
Volume141
DOIs
Publication statusPublished - 16 Jan 2020

Bibliographical note

Funding Information:
HBW and VMHC received unrestricted grants from Novartis Pharma BV.CAUG reports unrestricted grants from: Boehringer Ingelheim, Astellas, Celgene, Sanofi, Janssen-Cilag, Bayer, Amgen, Gemzyme, Merck, Gilead, Novartis, Glycostem Therapeutics, Astra Zeneca, Roche, outside the submitted work.SS reports grants and personal fees from Varian Medical Systems, ViewRay Inc., AstraZeneca, Celgene, and Eli Lily, outside the submitted work.

Funding Information:
CAUG reports unrestricted grants from: Boehringer Ingelheim , Astellas , Celgene , Sanofi , Janssen-Cilag , Bayer , Amgen , Gemzyme , Merck , Gilead , Novartis , Glycostem Therapeutics , Astra Zeneca , Roche , outside the submitted work.

Funding Information:
HBW and VMHC received unrestricted grants from Novartis Pharma BV .

Publisher Copyright:
© 2020 The Authors

Fingerprint

Dive into the research topics of 'Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study'. Together they form a unique fingerprint.

Cite this